![Page 1: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/1.jpg)
DR. TAHSIN.N
HYPERTROPHIC CARDIOMYOPATHY
DIAGNOSIS AND MANAGEMENT
![Page 2: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/2.jpg)
Symptoms
Symptoms of heart failure - preserved LV function - at any age
• Exertional dyspnea • Fatigue • Orthopnea or PND
Chest pain - typical angina pectoris or atypical - silent myocardial ischemia
Syncope (or near-syncope) and lightheadedness ---- - arrhythmias and outflow obstruction.
Symptoms and LV obstruction – No correlation
![Page 3: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/3.jpg)
Physical FindingsWith outflow obstruction
Arterial pulses rapid rise - with bisferiens contourDouble or triple apical impulses may be palpable
– Outward systolic thrust - ventricular contraction – Presystolic accentuated atrial contraction.
Medium-pitch ESM at the lower left sternal border and apex Loud murmurs > 3/6 - LV outflow gradients >30 mm Hg
Without subaortic gradients Subtle - with no or soft systolic murmurForceful apical impulse
![Page 4: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/4.jpg)
ECG
Abnormal - >90% of pts & >75% of asymptomatic relatives
– Increased voltages consistent with LV hypertrophy– ST-T changes - marked T wave inversion in the lateral precordial leads– Left atrial enlargement– Deep and narrow Q waves – Diminished R waves in the lateral precordial leads.
Normal ECG - 5% of pts – Less severe phenotype and favorable course– Not predictive of future sudden death
Increased voltages – Weakly correlated with the magnitude of LV hypertrophy – Do not distinguish the obstructive and nonobstructive forms
![Page 5: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/5.jpg)
![Page 6: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/6.jpg)
Holter
• Supraventricular tachycardia (46 percent)• Premature ventricular contractions (43 percent) • Nonsustained ventricular tachycardia (26 percent)• Atrial fibrillation (25 to 30 percent ) • Preexcitation has also been associated with HCM
![Page 7: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/7.jpg)
Serum C-terminal propeptide of type I procollagen (PICP)
Elevated levels PICP indicated increased myocardial collagen synthesis in sarcomere-mutation carriers without overt disease.
Profibrotic state preceded left ventricular hypertrophy or fibrosis visible on MRI.
![Page 8: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/8.jpg)
ECHOCARDIOGRAPHY
• Diffuse hypertrophy of the ventricular septum and anterolateral free wall (70% to 75%)
• Basal septal hypertrophy (10% to 15%) • Concentric hypertrophy (5%)• Apical hypertrophy (<5%) • Hypertrophy of the lateral wall (1% to 2%).• Mitral annulus velocity, Ea - status of myocardial relaxation -
reduced in most patients with HCM
![Page 9: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/9.jpg)
![Page 10: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/10.jpg)
![Page 11: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/11.jpg)
![Page 12: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/12.jpg)
![Page 13: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/13.jpg)
![Page 14: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/14.jpg)
![Page 15: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/15.jpg)
Late-peaking dagger-shaped appearance
![Page 16: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/16.jpg)
Dynamic LVOT obstruction - DDs
• Elderly patients with hypertension treated with vasodilators, diuretics or digoxin
• Postoperative period intravascular volume depletion and inotropic use.
• AS after AVR• Mitral valve prolapse after MVR• Acute anterior-apical MI• Some patients with apical ballooning
![Page 17: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/17.jpg)
Mimicking Hypertrophic Cardiomyopathy
• Chronic hypertension• RV hypertrophy• cardiac amyloidosis • Athlete's heart• Pheochromocytoma• Long-term hemodialysis• Fabry disease• Friedreich ataxia.
Apical hypertrophy - apical cavity obliteration caused by hypereosinophilic syndrome or noncompaction.
![Page 18: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/18.jpg)
Athlete's Heart Vs Hypertrophic Cardiomyopathy
HCM• Can be asymmetric• Wall thickness: > 15 mm• LA: > 40 mm• LVEDD : < 45 mm
• Diastolic function: always abnormal
Athletic heart• Concentric & regresses• < 15 mm• < 40 mm• > 45 mm• Normal
![Page 19: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/19.jpg)
CMR
More accurate than echoCan detect 6% more hypertrophy Accurate measurement of thicknessShould be done in
Poor echo windowDiscrepancy between Clinical findings / ECG / Echo
![Page 20: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/20.jpg)
CMR
Increased LV mass index – not sensitive – 20% HCM normal
Better differentiation between physiologcal & pathological LVH
End-diastolic wall thickness–to–cavity volume ratio < 0.15 mm/mL/m2
Lack of LGE of the ventricular myocardium
![Page 21: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/21.jpg)
CMR - Poor Prognostic factors
• Markedly elevated LV mass index (men > 91 g/m2; women > 69 g/m2) was sensitive (100%)
• Maximal wall thickness of more than 30 mm was specific (91%) for cardiac deaths
• Right ventricular (RV) hypertrophy • Myocardial edema by T2-weighted imaging• LGE has been associated with
– Ventricular arrhythmias
– Progressive ventricular dilation
![Page 22: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/22.jpg)
CMR DE as an arrhythmogenic substrate.
![Page 23: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/23.jpg)
CMR
![Page 24: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/24.jpg)
CATH
• Dynamic intraventricular pressure gradient• Swan neck deformity in a banana-shaped ventricle• Spike-and-dome configuration – proximal aorta• Brockenbrough-Braunwald sign
![Page 25: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/25.jpg)
CATH
![Page 26: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/26.jpg)
Natural History
• Normal life expectancy
• Mortality – Adults – 1% / yr– Children - 2% / yr
• Subgroups at higher risk for important disease complications– sudden and unexpected death– progressive heart failure – atrial fibrillation (AF)
![Page 27: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/27.jpg)
Heart failure
NYHA III - IV [10 - 15 %]
• LV outflow obstruction• AF• Diastolic dysfunction• Microvascular dysfunction
![Page 28: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/28.jpg)
BURNT OUT HCM
• Burnt out HCM - 3%• Systolic dysfunction EF <50% • Associated with AF• Wall thinning and cavity dilation• Diffuse transmural scarring • Progression to refractory heart failure or sudden death is
frequent (10%/year) • Most reliable risk marker - a family history of the end stage
![Page 29: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/29.jpg)
MANAGEMENT
![Page 30: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/30.jpg)
General guidelines
• Screening all first-degree relatives is recommended• Echocardiography • Children & participating in competitive athletics Every 12 to
18 months • Adults no competitive athletics - every 5 years• Counseled against engaging in competitive athletics• Maintain hydration
![Page 31: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/31.jpg)
Sudden Death & Risk stratification
• Primary ventricular tachycardia and ventricular fibrillation• Adolescents and young adults <30 to 35 years of age• Most common cause of Athletic field deaths• Death most commonly occur at rest
![Page 32: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/32.jpg)
High RiskSecondary prevention
1. Prior cardiac arrest 2. Sustained ventricular tachycardia
Primary prevention one or more of the following
3. Family history of one or more premature HCM-related deaths, particularly if sudden and multiple
4. Unexplained syncope, especially if recent and in the young 5. Hypotensive or attenuated blood pressure response to exercise6. Multiple, repetitive (or prolonged) NSVT on Holter7. Massive LVH (wall thickness, ≥30 mm), particularly in young patients
![Page 33: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/33.jpg)
![Page 34: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/34.jpg)
Potential arbitrators
• When level of risk judged - ambiguous on the basis of conventional markers
1. CMR - delayed enhancement 2. Thin-walled akinetic LV apical aneurysms 3. End-stage phase4. Percutaneous alcohol septal ablation
• Very limited prognostic significance can be attributed to specific HCM-causing mutations
![Page 35: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/35.jpg)
Prevention of SCD - ICD
![Page 36: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/36.jpg)
Copyright © American Heart Association
![Page 37: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/37.jpg)
• Prophylactic - empiric treatment with amiodarone – Obsolete• Amiodarone may be used in pts with AF
![Page 38: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/38.jpg)
Medical Treatment
• Empirical & highly variableBeta blockers
• Slowing heart rate • Reducing force of LV contraction• Augmenting ventricular filling and relaxation • Decreasing myocardial oxygen consumption • Long-acting preparations - propranolol, atenolol, metoprolol
or nadolol• Blunt LV outflow gradient triggered by physiologic exercise.• Target resting heart rate - 60 beats/min • May require up to 400 mg equivalent of metoprolol
![Page 39: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/39.jpg)
Verapamil
Improves symptoms and exercise capacity (patients without marked obstruction to LV outflow)
Beneficial effect on ventricular relaxation and fillingBetter angina control than BBHemodynamic deterioration with CCB agents - lowering of the
afterload in the presence of severe outflow tract gradients and high diastolic filling pressures
![Page 40: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/40.jpg)
Disopyramide Negative inotropic effect decreases the gradient and improve
symptoms. Concomitant beta blockade may be important to prevent rapid
atrioventricular node conductionBetween 300 and 600 mg/d The corrected QT interval must be monitored Anticholinergic side effects in older patients
Diuretic agents may be judiciously administeredEither beta blockers or verapamil initially No advantage by combinations of BB & CCBDisopyramide may be combined with BB or CCB
![Page 41: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/41.jpg)
EXPERIMENTAL TREATMENTSPerhexiline Incrs. Calcium sensitivity – Incrs. Contractility – Hypertrophy –
Abnl.energy utilisationImproved Energy utilisationDiltiazem Blocks L type Ca channelsTo prevent HypertrophyARB s To block TGF beta – Prevent Fibrosis
![Page 42: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/42.jpg)
![Page 43: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/43.jpg)
Surgical myectomy1. Drug-refractory heart failure symptoms2. NYHA Classes III and IV3. LV outflow obstruction
– Rest - gradient ≥ 30 mm Hg– Physiologic exercise - gradient ≥ 50 mm Hg
Transaortic resection of muscle from the proximal to midseptal region.( Upto PM)
Operative mortality <1 percentMaintain long-lasting improvement in symptoms and exercise
capacityMortality may be improved after septal myectomy
![Page 44: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/44.jpg)
DDD Pacing
• Objective measurements of exercise capacity did not differ significantly
• Overall decrease in outflow tract gradient (25 to 40 percent of baseline)
• Role of dual-chamber pacing - patients at high risk for other therapeutic modalities.
• Candidates for dual-chamber pacing
– Significant bradycardia in which pacing may allow an increased dosage of medication
– Patients who need ICD as a primary treatment
![Page 45: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/45.jpg)
Alcohol Septal Ablation
• Outflow tract gradient is reduced from a mean of 60 to 70 mm of mercury often to <20 mm of mercury
• 80–85 % symptomatic improvement• Complications
– complete heart block < 10 %– coronary dissections – large myocardial infarctions – ventricular septal defects– myocardial perforations– ventricular fibrillation
![Page 46: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/46.jpg)
• Septal ablation is not as efficacious as septal myectomy in eliminating the outflow tract obstruction
• Guidelines – severe medication-refractory symptoms– Risk of surgical septal myectomy increased - comorbidities
![Page 47: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/47.jpg)
Conclusion SA does seem to show promise in treatment of HOCM owing to similar mortality rates as well as functional status compared with SM; however, the caveat is increased conduction abnormalities and a higher post-intervention LVOTG. The choice of treatment strategy should be made after a thorough discussion of the procedures with the individual patient. (J Am Coll Cardiol 2010;55:823–34)
![Page 48: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/48.jpg)
Conclusions ERASH is a new therapeutic option in the treatment of HOCM, allowing significant and sustained reduction of the LVOT gradient as well as symptomatic improvement with acceptable safety by inducing a discrete septal contraction disorder. It may be suitable for patients not amenable to transcoronary ablation of septal hypertrophy or myectomy.
![Page 49: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/49.jpg)
![Page 50: DR. TAHSIN.N HYPERTROPHIC CARDIOMYOPATHY DIAGNOSIS AND MANAGEMENT](https://reader038.vdocument.in/reader038/viewer/2022103122/56649ca65503460f94967be6/html5/thumbnails/50.jpg)
Thank You